Most recently, Mr Brandt served as Pfizer’s president – US pharmaceuticals operations, where he helped deliver revenue and earnings growth while engineering major change within Pfizer’s US pharmaceuticals organization.
As CEO, Mr Brandt succeeds interim CEO Jeffrey Eisenberg, who will remain with Noven as executive vice president. The board appointed Mr Eisenberg to the interim leadership position following the January 2008 retirement of Robert Strauss.
Wayne Yetter, Noven’s chairman, said: “We could not be more pleased to have an executive with Peter’s background, experience and vision join the Noven team. Just as he led the pharmaceutical operations of one of the largest and most established companies in the world, we are confident that Peter is the ideal executive to lead Noven’s transformation, strategy and growth in the years ahead.”